Worldwide COVID-19 testing continues to ramp up consistently, predominantly using RT-PCR as the “gold standard”. However, more sensitive testing applications are now being introduced. We are proud to announce that Helix has received emergency use authorization (EUA) from the FDA for COVID-19 testing using next generation sequencing (NGS) with iSWAB-Microbiome as the collection method. Using NGS for COVID testing allows for greater in-depth interrogation of samples, leading to more accurate testing results and flexibility for the use of high-throughput automation.
Ultimately, what matters most about COVID-19 testing is that the viral RNA remains stable from point of collection to processing. If not transported with cold chain methods and processed within 48-72 hours, a positive sample that has been sitting in traditional VTM/MTM could end up yielding false-negative results due to RNA degradation. Our non-toxic iSWAB-Microbiome sample collection technology has proven to maintain viral RNA integrity for weeks after collection while also showing complete compatibility with multiple extraction chemistries, downstream applications, and automation platforms making it a perfect fit for COVID-19 sample collection and transport.
Read More Here: Helix COVID-19 NGS Test – EUA Summary
Candida Data Using iSWAB In Response to New Infectious Diseases...
A deadly fungal infection, Candida Auris, is becoming a serious threat. This drug-resistant strain is deadly for those with weakened immune systems and is spreading at an alarming rate. The READ MORE
Top Reasons to Ditch Your Current VTM. Upgrade your Viral…...
Mawi DNA has developed iSWAB-RC-EL, an FDA approved sample collection device for transport and storage of samples suspected of containing an infectious disease*. Why iSWAB-RC-EL is the superior op...
READ MOREMawi DNA Announces Dr. Bouzyk as New Board Member!...
It is with great delight and excitement that we announce that Dr. READ MORE